Please wait while the formulary information is being retrieved.
ABRYSVO (respiratory syncytial virus vaccine, preF A and B/PF)
- respiratory syncytial virus pneumonia prevention
120 mcg/0.5 mL intramuscular solution
- Inject 0.5 milliliter (120 mcg) by intramuscular route once
Default screening record
- Inject 0.5 milliliter (120 mcg) by intramuscular route once
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Immunosuppression
ABRYSVO (respiratory syncytial virus vaccine, preF A and B/PF)
- respiratory syncytial virus pneumonia prevention
- None
- Fatigue
- Headache disorder
- Injection site pain
- Myalgia
More Frequent
Severe
Less Severe
- None
- Arthralgia
- Diarrhea
- Injection site erythema
- Nausea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Guillain-barre syndrome
Less Severe
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Respiratory syncytial virus vaccin
No pediatric safety and efficacy established.
- 1 Day – 18 Years
- No pediatric safety and efficacy established.
Respiratory Syncytial Virus Vaccine
- Severity Level:
2
- Additional Notes: Not indicated in persons less than 60 yr old; preterm birth reported
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Respiratory Syncytial Virus Vaccine
Insufficient human data; not approved for use in persons <60 years old
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data; not approved for use in persons <60 years old |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Respiratory syncytial virus pneumonia prevention | |
| Z23 | Encounter for immunization |
| Z29.11 | Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSv) |
| Z29.89 | Encounter for other specified prophylactic measures |
| RSV vaccine at 32-36 wks gest to prevent RSV in infant | |
| Z23 | Encounter for immunization |
| 0-9 | A-Z |
|---|---|
| Z23 | Encounter for immunization |
| Z23 | Encounter for immunization |
| Z29.11 | Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSv) |
| Z29.89 | Encounter for other specified prophylactic measures |
Formulary Reference Tool